P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000973044.21308.32 |
| _version_ | 1827331426050113536 |
|---|---|
| author | Sebastian Birndt Jakob Hammersen Konstanze Döhner Philipp Reuken Paul Sauerbrey Felicitas La Rosée Markus Pfirrmann Christian Fabisch Gerald Illerhaus Manfred Weiß Karl Träger Hinrich Bremer Daniel Drömann Sylke Schneider Paul La Rosee Andreas Hochhaus |
| author_facet | Sebastian Birndt Jakob Hammersen Konstanze Döhner Philipp Reuken Paul Sauerbrey Felicitas La Rosée Markus Pfirrmann Christian Fabisch Gerald Illerhaus Manfred Weiß Karl Träger Hinrich Bremer Daniel Drömann Sylke Schneider Paul La Rosee Andreas Hochhaus |
| author_sort | Sebastian Birndt |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:36:03Z |
| format | Article |
| id | doaj.art-0d498c619358404e9739a8851451a407 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:36:03Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0d498c619358404e9739a8851451a4072024-03-03T09:43:16ZengWileyHemaSphere2572-92412023-08-017e213083210.1097/01.HS9.0000973044.21308.32202308003-01435P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIALSebastian Birndt0Jakob Hammersen1Konstanze Döhner2Philipp Reuken3Paul Sauerbrey4Felicitas La Rosée5Markus Pfirrmann6Christian Fabisch7Gerald Illerhaus8Manfred Weiß9Karl Träger10Hinrich Bremer11Daniel Drömann12Sylke Schneider13Paul La Rosee14Andreas Hochhaus151 Jena University Hospital - Hospital Lobeda, Jena, Germany1 Jena University Hospital - Hospital Lobeda, Jena, Germany2 Universitätsklinikum Ulm Klinik für Innere Medizin III - Hämatologie, Onkologie, Rheumatologie, Infektionskrank., Ulm, Germany1 Jena University Hospital - Hospital Lobeda, Jena, Germany1 Jena University Hospital - Hospital Lobeda, Jena, Germany3 Technical University of Dresden Medical School, Dresden, Germany4 Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, IBE, München, Germany1 Jena University Hospital - Hospital Lobeda, Jena, Germany5 Katharinen Hospital, Stuttgart, Germany6 University Hospital Of Ulm, Ulm, Germany6 University Hospital Of Ulm, Ulm, Germany7 Lungenzentrum Donaueschingen, Donaueschingen, Germany8 Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany9 SRH Wald-Klinikum Gera, Gera, Germany10 Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany1 Jena University Hospital - Hospital Lobeda, Jena, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000973044.21308.32 |
| spellingShingle | Sebastian Birndt Jakob Hammersen Konstanze Döhner Philipp Reuken Paul Sauerbrey Felicitas La Rosée Markus Pfirrmann Christian Fabisch Gerald Illerhaus Manfred Weiß Karl Träger Hinrich Bremer Daniel Drömann Sylke Schneider Paul La Rosee Andreas Hochhaus P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL HemaSphere |
| title | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_full | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_fullStr | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_full_unstemmed | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_short | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_sort | p1542 ruxolitinib in covid 19 patients with defined hyperinflammation the ruxcoflam trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000973044.21308.32 |
| work_keys_str_mv | AT sebastianbirndt p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT jakobhammersen p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT konstanzedohner p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT philippreuken p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT paulsauerbrey p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT felicitaslarosee p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT markuspfirrmann p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT christianfabisch p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT geraldillerhaus p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT manfredweiß p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT karltrager p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT hinrichbremer p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT danieldromann p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT sylkeschneider p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT paullarosee p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT andreashochhaus p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial |